PMID- 26105582
OWN - NLM
STAT- MEDLINE
DCOM- 20160412
LR  - 20181202
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 109
IP  - 3
DP  - 2015 Sep
TI  - Fenofibrate reduces inflammation in obese patients with or without type 2 
      diabetes mellitus via sirtuin 1/fetuin A axis.
PG  - 513-20
LID - S0168-8227(15)00273-9 [pii]
LID - 10.1016/j.diabres.2015.05.043 [doi]
AB  - AIMS: The aim of the current study is to investigate the effect of fenofibrate 
      alone and in combination with pioglitazone on serum sirtuin 1 and fetuin A of 
      obese patients with Type 2 Diabetes Mellitus (T2DM). METHODS: Intervention effect 
      on inflammatory parameters was assessed before and after treatment. The study was 
      conducted on 60 postmenopausal females of whom, only 44 patients completed the 
      study. They were distributed as follows; obese patients without T2DM (n=15) who 
      administered fenofibrate (160 mg/day) once for 8 weeks, obese patients with T2DM 
      (n=15) who administered fenofibrate (160 mg/day) once for 8 weeks, obese patients 
      with T2DM (n=14) who administered fenofibrate (160 mg/day) and pioglitazone (15 
      mg/day) combination once for 8 weeks. We measured fasting plasma glucose, 
      glycated hemoglobin (HbA1c), serum lipids. Inflammatory markers (high sensitivity 
      C-reactive protein "hs-CRP", interleukin-6 "IL-6", fetuin A, and sirtuin 1) of 
      patients were measured in serum using enzyme-linked immunoassay (ELISA) kits. 
      RESULTS: Sirtuin 1 levels in obese patients with T2DM were significantly lower 
      than its levels in obese patients while fetuin A levels were significantly higher 
      (P<0.001). Fenofibrate, alone and in combination with pioglitazone, significantly 
      decreased triacylglycerol, hs-CRP, IL-6, fetuin A and increased sirtuin 1 levels 
      (P<0.001) which suggests that it can be used to delay the complications of 
      obesity and T2DM. There is a strong correlation between fetuin A, sirtuin 1, IL-6 
      and hs-CRP levels suggesting a shared common pathway. CONCLUSIONS: Fenofibrate 
      was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese 
      patients. TRIAL NUMBER: PACTR201407000856135.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Noureldein, Mohamed H
AU  - Noureldein MH
AD  - BSc of Pharmaceutical Sciences, Teaching Assistant at Biochemistry Department, 
      Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
FAU - Abd El-Razek, Rania S
AU  - Abd El-Razek RS
AD  - Lecturer of Biochemistry, Biochemistry Department, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt.
FAU - El-Hefnawy, Mohamed H
AU  - El-Hefnawy MH
AD  - Professor of endocrinology and Dean of the National Institute of Diabetes and 
      Endocrinology (NIDE), Cairo, Egypt.
FAU - El-Mesallamy, Hala O
AU  - El-Mesallamy HO
AD  - Professor of Biochemistry and Vice Dean of Postgraduate and Research Affairs, 
      Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address: 
      hala.elmesallamy@hotmail.com.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20150611
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Lipids)
RN  - 0 (Thiazolidinediones)
RN  - 0 (alpha-2-HS-Glycoprotein)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - U202363UOS (Fenofibrate)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aged
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Female
MH  - Fenofibrate/administration & dosage/*therapeutic use
MH  - Humans
MH  - Inflammation/complications/*drug therapy/metabolism
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications/*drug therapy/metabolism
MH  - Pioglitazone
MH  - Signal Transduction/physiology
MH  - Sirtuin 1/*metabolism
MH  - Thiazolidinediones/administration & dosage
MH  - alpha-2-HS-Glycoprotein/*metabolism
OTO - NOTNLM
OT  - Fenofibrate
OT  - Fetuin A
OT  - Obesity
OT  - Pioglitazone
OT  - Sirtuin 1
OT  - T2DM
EDAT- 2015/06/25 06:00
MHDA- 2016/04/14 06:00
CRDT- 2015/06/25 06:00
PHST- 2015/02/25 00:00 [received]
PHST- 2015/05/07 00:00 [revised]
PHST- 2015/05/19 00:00 [accepted]
PHST- 2015/06/25 06:00 [entrez]
PHST- 2015/06/25 06:00 [pubmed]
PHST- 2016/04/14 06:00 [medline]
AID - S0168-8227(15)00273-9 [pii]
AID - 10.1016/j.diabres.2015.05.043 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2015 Sep;109(3):513-20. doi: 
      10.1016/j.diabres.2015.05.043. Epub 2015 Jun 11.